source
- Typewriter secures $56M to advance jumping-gene platform and in vivo CAR-T therapiesTypewriter, a biotech startup, announced it has closed a $56 million financing round. The capital will be used to develop its jumping-gene platform, which seeks to deliver full genes without viral…
- Novartis halts CD19 CAR-T trial after three deaths, Bristol Myers also pauses similar programNovartis announced a pause to its CD19-directed CAR-T cell therapy trials after three patients experienced fatal immune reactions. The company said the deaths were linked to a severe cytokine relea…